Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Bladder

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.
Bladder
II
Davis, Nancy
NCT04003610
VICCURO19134

A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC

Bladder

A study to evaluate nivolumab + chemotherapy or nivolumab / BMS-986205 + chemotherapy followed by continued Immuno-Oncology therapy after radical cystectomy (RC) compared with neoadjuvant standard of care (SOC) chemotherapy alone in patients with muscle-invasive bladder cancer (MIBC)
Bladder
III
Davis, Nancy
NCT03661320
VICCURO18152

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: